The countdown has officially begun. From May 11–14, 2026, the global biopharmaceutical community will descend upon the Hynes Convention Center in the heart of Boston for TIDES USA: Oligonucleotide & Peptide Therapeutics.
As we stand on the precipice of a new era in genetic medicine and targeted delivery, this year’s conference promises to be the most influential yet. With over 200 presentations across six concurrent tracks, TIDES remains the premier forum for those at the intersection of discovery, CMC (Chemistry, Manufacturing, and Controls), and clinical success.
What to Expect at Tides 2026
Boston, the world’s leading biotech hub, provides the perfect backdrop for this year’s discussions. The 2026 agenda is packed with heavy hitters, including keynote sessions from industry legends like Robert S. Langer of MIT and Anastasia Khvorova from the UMass Chan Medical School.
The program is meticulously organized into specialized tracks to ensure deep dives into the industry’s 4 most pressing challenges:
-
Oligonucleotide Discovery & CMC: Mastering next-gen analytical techniques and scaling manufacturing.
-
Peptide Innovation: Exploring oral delivery breakthroughs and complex molecule synthesis.
-
mRNA & Genome Editing: Moving beyond COVID-19 to target rare diseases and oncology.
-
Drug Delivery Innovations: Overcoming the “translational chasm” with novel scaffolds and targeted devices.
The Engine of Modern Drug Development
The TIDES conference is more than just a networking event; it is a critical catalyst for modern drug development. In an industry where emerging modalities like oligonucleotides and peptides often face a staggering 73% attrition rate in early development, TIDES serves as the collaborative laboratory where these “translational cliffs” are dismantled. By bringing together medicinal chemists, process scientists, and regulatory experts under one roof, the event fosters the cross-functional alignment necessary to move a molecule from a high-risk lead to a GMP-ready therapeutic. This synergy is vital for accelerating the production of life-saving treatments for rare diseases, oncology, and chronic conditions that were previously considered “undruggable.”
Beyond the Podium
While the sessions provide the roadmap, the Exhibition Hall (featuring over 75 live booths) provides the tools. Companies like Cyagen, Nitto Avecia, and Bachem will be showcasing the latest in AI-assisted workflows, advanced mouse models, and solid-phase peptide synthesis technologies. Whether you are looking for a CDMO partner or the latest in purification membranes, the expo floor is where the business of biotech happens.
Frequently Asked Questions (FAQ) About Tides
When and where is TIDES USA 2026 taking place?
The conference will be held from May 11–14, 2026, at the Hynes Convention Center, located at 900 Boylston St, Boston, MA.
Who should attend TIDES?
The event is designed for scientists, C-level executives, and manufacturing experts involved in the discovery and development of oligonucleotides, peptides, mRNA, and genome editing therapeutics.
What are the primary registration tracks?
The 2026 conference features six main tracks:
-
Oligonucleotide CMC
-
Oligonucleotide Discovery
-
Peptide CMC
-
Peptide Discovery
-
mRNA/Genome Editing
-
Drug Delivery Innovations
Are there options for virtual attendance?
Yes, TIDES USA 2026 offers a Digital Experience package which includes access to on-demand session recordings and a digital networking platform to connect with both live and virtual attendees.
How much does registration cost?
Rates vary based on the package and attendee type. As of the current schedule:
-
Industry Rate: Approximately $2,699 to $3,499.
-
Academic/Government Rate: Approximately $949 to $1,249.
(Note: Early bird discounts and group rates are typically available).
Is there a poster session?
Absolutely. There are live poster presentations in the poster hall throughout the event, offering a platform for researchers to showcase their latest findings to a global audience.
Alex has 20+ years of experience in the CMC space, specializing in CDMO/CRO management, analytical development, technology transfer, quality and regulatory compliance for various drug modalities across multiple product stages.
Reach out to Alex on LinkedIn.
